NYSE: AVTR · Medical Instruments & Supplies
Avantor (AVTR) fair value and price range
As of 31 Oct 2026, Faircurve's model values Avantor (AVTR) at $19.12 a share. The stock last closed at $15.14, which puts the model's fair value 26.3% above the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 5 Nov 2026. Avantor, Inc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 31 Oct 2026 moved the fair value from $20.28 to $19.12 (-5.7%). The model shifted weight between the company's own multiple and its peers': most of the move.
What the model makes of itThe price of $15.14 is 26.3% below it. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What's nextNext report on 10 Feb 2027. Options prices imply a move of about 14% either way over the next month. On the model's Scorecard Leaders list since 19 Oct 2026 (a strategy with a proving record). The next weekly run is on Saturday 7 Nov 2026.
What price range does the model give AVTR?
The calibrated range for AVTR over 63 trading days is $13.14 to $18.02. It sits around the last close, and its width comes from the volatility that AVTR's own options imply (48% a year), calibrated weekly against realised prices (n = 6,661 past valuations, refreshed 31 Oct 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $10.17 to $32.57. In 60% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 31 Oct 2026
Avantor, Inc. is a global provider of vital products and specialised services. The company was established in 1904 and is based in Radnor, Pennsylvania.
On 31 Oct 2026, Faircurve's model put the fair value at $19.12 a share. The previous run, on 24 Oct 2026, gave $20.28, a move of -5.7%. The model says it shifted weight between the company's own multiple and its peers', which accounts for most of the move. The calibrated range over 63 trading days is $13.75 to $18.35. Ranges built this way held the price 60% of the time at this horizon, across 6,661 past valuations. The model grades the evidence as low, so no verdict is shown.
The model scores the company's overall quality at 51 out of 100 against comparable companies. Capital discipline is highest at 81, with net buybacks of 0.7% against a peer median of 0.1%. Growth quality is lowest at 26, with trailing revenue growth of -3.4% against a peer median of 3.9%. The model compares the company with Repligen, Cooper, Baxter, AptarGroup, Solventum, Merit Medical and ICU Medical.
Written from the figures on this page for the 31 Oct 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does AVTR report earnings, and how has the stock reacted?
Avantor's next earnings report is scheduled for 10 Feb 2027. Companies can move their dates.
Options prices on 5 Nov 2026 imply a move of about 12.9% in either direction through the nearest expiry, about 42 days out. That is the size the market is pricing, not a direction. AVTR's 30 day implied volatility works out to about 13.8% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across AVTR's last 8 reports, ignoring direction, was 12.0%.
What the options market has priced for a month's move in AVTR
How does AVTR score on business quality?
Avantor's overall quality score is 51 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 63 | 5.6%ROIC | 3.0% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 48 | 1.30xFCF / net income | 1.68x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 26 | -3.4%Revenue growth, trailing | 3.9% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 81 | 0.7%Net buybacks / market value | 0.1% |
| Balance sheetNet debt to EBITDA and interest coverage. | 43 | 3.54xNet debt / EBITDA | 0.83x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 50 | 6.0 ptsEBITDA margin downside volatility, 5y | 6.2 pts |
How does AVTR compare with similar companies?
The companies in medical instruments & supplies closest to Avantor in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| RGEN Repligen Corporation | $168.48 | $142.95 | -15.2% | Overvalued |
| COO The Cooper Companies, Inc. | $63.51 | $68.01 | +7.1% | Fairly valued |
| BAX Baxter International Inc. | $25.65 | $23.62 | -7.9% | Fairly valued |
| ATR AptarGroup, Inc. | $144.04 | $132.22 | -8.2% | Fairly valued |
| SOLV Solventum Corporation | $87.18 | $92.15 | +5.7% | Fairly valued |
| TFX Teleflex Incorporated | $152.15 | $142.86 | -6.1% | Low evidence grade |
| MMSI Merit Medical Systems, Inc. | $89.62 | $81.34 | -9.2% | Fairly valued |
| ICUI ICU Medical, Inc. | $167.65 | $193.63 | +15.5% | Undervalued |
What the comparable companies' multiples alone would give for AVTR, the peer-implied price, is $35.81 a share on this run. The fair value weighs that against the company's own multiple.
All medical instruments & supplies stocks ranked by gap to fair value
Avantor at a glance
Avantor, Inc., a company established in 1904 and based in Radnor, Pennsylvania, is a global provider of vital products and specialized services.
- Market value
- $10.9B
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Revenue expected, next twelve months
- $6.8B
- Consensus revenue growth, next fiscal year
- +1.8%
- Analysts with estimates
- 8
- Beta to the US market
- 0.59
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Avantor on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 24 Oct 2026 the model's fair value for AVTR was $20.28. As of 31 Oct 2026 it is $19.12, a change of -5.7%. The model shifted weight between the company's own multiple and its peers': most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Avantor's valuation
Is Avantor stock undervalued or overvalued?
Faircurve's model puts AVTR's fair value at $19.12 a share against a last close of $15.14, as of 31 Oct 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is AVTR's fair value?
$19.12 a share as of 31 Oct 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $10.17 to $32.57.
What price range does the model give AVTR?
$13.14 to $18.02 over 63 trading days. Ranges built this way held the price 60% of the time across 6,661 past valuations, refreshed 31 Oct 2026.
When does Avantor report earnings next?
The next report is scheduled for 10 Feb 2027. Companies can move their dates.
How much has AVTR moved on past earnings reports?
Across its last 8 reports the median two session move was 12.0%, ignoring direction. The largest was -26.7% around the report of 29 Oct 2025.
How confident is the model in this valuation?
The model's evidence grade for AVTR is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on AVTR
The model has an idea open on AVTR under Scorecard Leaders since 19 Oct 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on AVTR with their outcomes. A free account is enough.